EFFECT OF ESCITALOPRAM ALONE OR COMBINATION WITH SORAFENIB ON HEPG2 HEPATOCELLULAR CELL LINE PROLIFERATION

HEPATOCELLULAR CARCINOMA IS ONE OF THE MOST COMMON CANCERS. THE MAIN TREATMENT FOR HEPATOCELLULAR CANCERS IS SURGERY. DRUG TREATMENT CAN BE PERFORMED IN ADVANCED CASES AFTER SURGICAL TREATMENT OR RELAPSE THERAPY. SORAFENIB IS A DRUG THAT IS USED PRIMARILY IN THE TREATMENT OF HEPATOCELLULAR CANCER. E...

Full description

Saved in:
Bibliographic Details
Published in:Research and science today 2020-04, Vol.19 (1), p.201-2010
Main Authors: Ozunal, Zeynep Gunes, DONMEZ CAKIL, Yaprak, SAGLAM, Esra, Aktas, Ranan Gunhan
Format: Article
Language:English
Subjects:
Antidepressants
Biotechnology
Citalopram
Drug dosages
Enzymes
Health and medicine and law
Liver cancer
Mental depression
Regression analysis
Serotonin
Serotonin uptake inhibitors
Synergistic effect
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HEPATOCELLULAR CARCINOMA IS ONE OF THE MOST COMMON CANCERS. THE MAIN TREATMENT FOR HEPATOCELLULAR CANCERS IS SURGERY. DRUG TREATMENT CAN BE PERFORMED IN ADVANCED CASES AFTER SURGICAL TREATMENT OR RELAPSE THERAPY. SORAFENIB IS A DRUG THAT IS USED PRIMARILY IN THE TREATMENT OF HEPATOCELLULAR CANCER. ESCITALOPRAM IS A DRUG IN THE SEROTONIN REUPTAKE INHIBITOR GROUP USED TO TREAT DEPRESSION. THERE ARE STUDIES SHOWING THE EFFECT OF ESCITALOPRAM ON PROLIFERATION. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE USE OF ESCITALOPRAM ALONE AND IN COMBINATION WITH SORAFENIB IN LIVER CANCER. THE EFFECT OF ESCITALOPRAM AND IN COMBINATION ON PROLIFERATION OF HEPATOCELLULAR CELL LINES WAS ASSESSED BY XTT PROLIFERATION ASSAY. THE HALF INHIBITING CONCENTRATİON (IC 50) WAS CALCULATED BY REGRESSION ANALYSIS, PHOTOGRAPHED UNDER AN İNVERTED MİCROSCOPE. THE SYNERGISTIC EFFECT HAS BEEN EVALUATED. THE EFFECT ON MORPHOLOGİCAL CHANGES WAS VISUALIZED UNDER THE INVERTED MICROSCOPE. THE RESULTS OF OUR STUDY CONFIRM THE SYNERGISTIC EFFECT OF USE OF ESCITALOPRAM IN COMBINATION WITH SORAFENIB IN LIVER CANCER. PROSPECTIVE RANDOMIZED TRIALS ARE NEEDED TO EVALUATE ITS CLINICAL USE.
ISSN:2247-4455
2285-9632
DOI:10.38173/RST.2020.19.1.20:201-210